1α,25‐Dihydroxyvitamin D3modulates human adipocyte metabolism via nongenomic action
- 15 October 2001
- journal article
- fj express-summaries
- Published by Wiley in The FASEB Journal
- Vol. 15 (14), 1-15
- https://doi.org/10.1096/fj.01-0584fje
Abstract
We reported recently that suppression of the renal 1alpha,25-dihyroxyvitamin D3 (1lpha,25-(OH)2-D3) production in aP2-agouti transgenic mice by increasing dietary calcium decreases adipocyte intracellular Ca2+ ([Ca2+]i), stimulates lipolysis, inhibits lipogenesis, and reduces adiposity. However, it was not clear whether this modulation of adipocyte metabolism by dietary calcium is a direct effect of inhibition of 1alpha,25-(OH)2-D3-induced [Ca2+]i. Accordingly, we have now evaluated the direct role of 1alpha,25-(OH)2-D3. Human adipocytes exhibited a 1alpha,25-(OH)2-D3 dose-responsive (1-50 nM) increase in [Ca2+]i (P<0.01). This action was mimicked by 1alpha,25-dihyroxylumisterol3 (1alpha,25-(OH)2-lumisterol3) (P<0.001), a specific agonist for a putative membrane vitamin D receptor (mVDR), and completely prevented by 1b,25-dihydroxyvitamin D3 (1beta,25-(OH)2-D3), a specific antagonist for the mVDR. Similarly, 1alpha,25-(OH)2-D3 (5 nM) caused 50%-100% increases in adipocyte fatty acid synthase (FAS) expression and activity (P<0.02), a 61% increase in glycerol-3-phosphate dehydrogenase (GPDH) activity (P<0.01), and an 80% inhibition of isoproterenol-stimulated lipolysis (P<0.001), whereas 1beta,25-(OH)2-D3 completely blocked all these effects. Notably, 1alpha,25-(OH)2-lumisterol3 exerted more potent effects in modulating adipocyte lipid metabolism, with 2.5- to 3.0-fold increases in FAS expression and activity (P<0.001) and a threefold increase in GPDH activity (P<0.001). Also 1alpha,25-(OH)2-lumisterol3 was approximately twice as potent in inhibiting basal lipolysis (P<0.025), whereas 1beta,25-(OH)2-D3 completely blocked all these effects. These data suggest that 1alpha,25-(OH)2-D3 modulates adipocyte Ca2+ signaling and, consequently, exerts a coordinated control over lipogenesis and lipolysis. Thus, a direct inhibition of 1alpha,25-(OH)2-D3-induced [Ca2+]i may contribute to an anti-obesity effect of dietary calcium, and the mVDR may represent an important target for obesity.Keywords
This publication has 33 references indexed in Scilit:
- Calcium Intake and Body WeightJournal of Clinical Endocrinology & Metabolism, 2000
- Receptors for 1α,25(OH)2D3: Past, Present, and FutureJournal of Bone and Mineral Research, 1998
- Identification of a Membrane Receptor for 1,25-Dihydroxyvitamin D3 Which Mediates Rapid Activation of Protein Kinase CJournal of Bone and Mineral Research, 1998
- Oral Calcium Supplementation Reduces Intraplatelet Free Calcium Concentration and Insulin Resistance in Essential Hypertensive PatientsHypertension, 1997
- 1β, 25(OH)2-vitamin D3 is an antagonist of 1α,25(OH)2-vitamin D3 stimulated transcaltachia (The rapid hormonal stimulation of intestinal calcium transport)Biochemical and Biophysical Research Communications, 1992
- 1α,25-Dihydroxyvitamin D3 rapidly increases cytosolic calcium in clonal rat osteosarcoma cells lacking the vitamin D ReceptorJournal of Bone and Mineral Research, 1991
- Possible role of cytosolic free calcium concentrations in mediating insulin resistance of obesity and hyperinsulinemia.JCI Insight, 1988
- Evidence of a probable role for 25-hydroxyvitamin D in the regulation of human calcium metabolismJournal of Bone and Mineral Research, 1988
- Evidence that obesity does not influence the vitamin D-endocrine system in blacksJournal of Bone and Mineral Research, 1986
- Evidence for alteration of the vitamin D-endocrine system in obese subjects.JCI Insight, 1985